The year 2025 marked a pivotal period of strategic transformation for INNOGEN-B (02591), as the company shifted from a pure research and development focus to a dual approach integrating R&D with commercialization. During the year, the company's core product, Esupagrutide α, successfully gained approval for its Type 2 Diabetes (T2D) indication, achieved commercial launch in mainland China and Macau, secured inclusion in the national medical insurance reimbursement list, and initiated overseas registration filings. Progress was also made in its pipeline for metabolic diseases. Benefiting from the commercialization of Esupagrutide α, INNOGEN-B recorded its first significant revenue in 2025, generating approximately RMB 132 million for the full year. However, this revenue milestone highlighted the typical growing pains faced by innovative biopharmaceutical companies in the early stages of commercialization. Due to increased R&D investment, expansion of the sales team, and intensified market development efforts, the company reported an annual loss of approximately RMB 341 million, representing a significant 95.4% year-on-year expansion of losses. Concurrently, a sharp rise in current liabilities heightened short-term debt repayment pressure. In the capital markets, INNOGEN-B's stock performance reflected cautious investor sentiment. After reaching an all-time high of HKD 74 shortly after its IPO, the stock trended downwards. By March 24, 2026, it had fallen to an intraday low of HKD 19.05, a decline of over 74% from its peak. As of the market close on April 2, 2026, the share price stood at HKD 20.86, reflecting a 31.92% decline for the year, indicating that market confidence still requires further restoration.
High R&D and sales expenditures significantly pressured profitability. Esupagrutide α is a humanized long-acting GLP-1 receptor agonist approved in China, characterized by an ultra-long half-life and favorable safety and tolerability profiles, demonstrating differentiated potential in dosing convenience, blood glucose control, and metabolic benefits. The product was approved for T2D treatment in 2025 and was included in China's National Reimbursement Drug List (NRDL) effective January 1, 2026. It was also incorporated into the "National Primary Care Diabetes Prevention and Management Guidelines (2025)," enhancing its academic recognition and potential for grassroots promotion. Beyond T2D, the company is advancing clinical development for the product in obesity, overweight, and MASH (metabolic dysfunction-associated steatohepatitis), with registration plans in certain overseas markets. In 2025, sales of Esupagrutide α constituted the primary revenue source for INNOGEN-B. Due to accounting policies that categorized pre-commercialization production costs as R&D expenses, the cost of sales for 2025 was only RMB 14.452 million, resulting in a gross profit margin of 89%. This high margin is a temporary outcome of specific accounting treatments and does not reflect the true full-cost profitability level. As production scales and operations mature, the gross margin is expected to normalize. Despite the impressive gross margin, the company reported a substantial net loss. The basic loss per share was RMB 0.79 in 2025, significantly wider than the RMB 0.42 loss in 2024, primarily due to high-intensity investments in R&D and sales that substantially exceeded the current revenue level. Furthermore, the commercial launches of Esupagrutide α for T2D in mainland China (February 2025) and Macau (September 2025) meant revenue was recognized for only part of the year, while associated expenses were accounted for over the full year, creating a temporary mismatch between investment and returns.
Analyzing the expense structure, R&D expenditures doubled from approximately RMB 103 million in 2024 to about RMB 206 million in 2025. This increase was mainly allocated to process optimization for Esupagrutide α production, clinical advancement for obesity and overweight indications, and related material inputs. Sales and distribution expenses surged dramatically from RMB 2.386 million to approximately RMB 177 million, driven by the rapid establishment of a commercial team that grew from 5 to 89 employees, alongside intensified academic promotion and channel development activities. The financial strain from this expense expansion was partly reflected in the company's liabilities. By the end of 2025, current liabilities increased by 265.4% from approximately RMB 138 million in 2024 to about RMB 505 million. The debt-to-asset ratio rose by 18 percentage points year-on-year to 33%. Specifically, unsecured interest-bearing bank loans due within one year surged from RMB 9.9 million to RMB 150 million. Payables related to CDMO production and process improvements increased by RMB 134 million, coupled with marketing-related accrued expenses of RMB 88.9 million, amplifying operational payable pressure and correspondingly increasing short-term debt repayment obligations.
The GLP-1 sector for weight loss is not immune to intense competition. To address performance challenges and short-term debt pressure, INNOGEN-B's path to improvement is clear: accelerate the sales ramp-up of its core product, Esupagrutide α. The company stated in its financial report that it expects to continue advancing the commercialization of the product for T2D in 2026. Successful execution of this plan would allow revenue growth to offset fixed cost pressures, gradually improving operating cash flow. Additionally, the ability of the metabolic disease pipeline to yield positive clinical results and market returns is a key focus area. Obesity and overweight represent a major expansion focus for the pipeline and a highly lucrative segment within the GLP-1 arena, with substantial market demand. The financial report indicated that INNOGEN-B continued its Phase III clinical study of Esupagrutide α for treating obesity and overweight in China throughout 2025, completing patient enrollment for this indication. Top-line data is expected to be released by the end of 2026. Esupagrutide α has demonstrated an ultra-long half-life of approximately 280 hours in overweight and obese patients and shows promising potential for weight management. In a Phase IIb study, a once-weekly 20mg dose regimen achieved a 10.6% weight reduction at 18 weeks without reaching a plateau, while a bi-weekly 20mg regimen resulted in a 9.7% weight reduction. The treatment also improved body composition, with an average increase in the muscle-to-fat ratio of 19.7%. Overseas, a Phase II study for obesity and overweight in Australia has completed enrollment, exploring various dosing regimens (weekly, bi-weekly, monthly) to pave the way for global clinical development. The company is also advancing a new indication for adolescent weight management, targeting an area with unmet clinical needs. It is important to note that while GLP-1 drugs hold strong growth prospects, translating this potential into tangible performance gains involves significant challenges. Many domestic and international pharmaceutical companies are exploring opportunities in the GLP-1 space, aggressively entering the weight loss market. For instance, Novo Nordisk's weight loss version of semaglutide launched in China in 2024. Following the expiration of its core compound patent on March 20, 2026, a wave of generic approvals is anticipated, which will intensify market competition and likely lead to significant price reductions. Furthermore, INNOGEN-B faces risks associated with overseas clinical development, including high costs, long cycles, and uncertain approval processes. Its drug candidates may not meet expectations in development, regulatory approval, or commercialization.
The year 2026 presents three critical tests for the company's transformation. First, the true sales traction of Esupaglutide α following its NRDL inclusion is paramount. As the current core revenue driver, the speed of channel coverage and sales growth will directly impact the improvement of operating cash flow and the pace of loss reduction. Second, the Phase III clinical data for the obesity and overweight indication is crucial. This indication represents a core blue-ocean market within the GLP-1 sector. If the data confirms the weight loss efficacy and safety advantages observed in Phase IIb, it will lay a critical foundation for subsequent New Drug Application (NDA) submissions and further expand the product's market potential. Third, progress in overseas registrations is vital. The company has submitted Biologics License Applications (BLAs) in markets like Hong Kong, Southeast Asia, and Latin America. Approval progress in these regions will be a significant milestone for its global strategy and provide new support for long-term growth. Given the increasingly competitive GLP-1 landscape, INNOGEN-B must leverage the differentiated advantages of its product in terms of adherence and safety, utilize the benefits of NRDL inclusion to accelerate market penetration, and rapidly increase its market share. For investors, the company remains in the typical high-investment cycle for innovative biopharma firms, with clear expectations for earnings volatility and cash flow pressure. Risks to monitor include clinical data falling short of expectations, slower-than-anticipated sales growth post-NRDL inclusion, and gross margin erosion due to price wars with generics. Investors should focus on key milestones in 2026, such as revenue figures, obesity clinical data, and overseas registration progress, assessing the company's value based on a comprehensive view of commercialization success and pipeline advancement rather than short-term profitability alone.
Comments